Home › Ulcerative Colitis › North Carolina › Fayetteville
Ulcerative Colitis clinical trials in Fayetteville, NC
4 studies for Ulcerative Colitis are looking for participants at sites in and around Fayetteville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Confirmatory Clinical Study in Active Ulcerative Colitis
RecruitingPhase 2
- Cross Creek Medical Clinic, Fayetteville
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RecruitingPhase 3
- Coastal Research Institute - Fayetteville, Fayetteville
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RecruitingPhase 3
- Cross Creek Medical Clinic - Site Number: 8400057, Fayetteville
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RecruitingPhase 3
- Cross Creek Medical Clinic - Site Number: 8400057, Fayetteville
About Ulcerative Colitis
Ulcerative Colitis (UC) can cause long-lasting swelling and ulcers in the large intestine. It is a type of inflammatory bowel disease. Find out more.
More about Ulcerative Colitis on MedlinePlus
Ulcerative Colitis trials in other cities
- New York City, NY23 studies
- Orlando, FL22 studies
- Miami, FL21 studies
- Houston, TX17 studies
- San Antonio, TX16 studies
- Chicago, IL15 studies
- Tacoma, WA15 studies
- San Diego, CA15 studies
- Tyler, TX14 studies
- Colorado Springs, CO14 studies
- Los Angeles, CA13 studies
- St. Louis, MO13 studies
Other studies in Fayetteville
- Steatotic Liver Disease6 studies
- Crohn's Disease4 studies
- Obesity4 studies
- Overweight4 studies
- Concussion4 studies
- Lupus3 studies
- Post-Traumatic Stress Disorder3 studies
- Liver Diseases3 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.